Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: A systematic review

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Anglemyer, Andrew ^a   Rutherford, George W ^a   Easterbrook, Philippa J ^b   Horvath, Tara ^a   Vitória, Marco ^b   Jan, Michael ^c   Doherty, Meg C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adolescents; adults; antiretroviral therapy; observational studies; randomized controlled trial; systematic review; WHO

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; TENOFOVIR;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; EARLY INTERVENTION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; DRUG ADMINISTRATION; HIV INFECTIONS; IMMUNOLOGY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; TIME;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; MULTICENTER STUDIES AS TOPIC; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901307096     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000232     Document Type: Review

References (53)

1. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl. pdf. [Accessed 26 January 2014]
2. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adults HIV infection. 2012 recommendation of the International Antiviral Society-USA Panel. J Am Med Assoc 2012; 308:387-402.
3. Ministère des Affaires Sociales et de la Santé, Conseil National du Sida, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales. Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts. Rapport 2013.http://www.sante. gouv.fr/IMG/pdf/Rapport-Morlat-2013-Mise-en-ligne.pdf. [Accessed 23 January 2014]
4. Ministério de Saúde, Departamento de DST, Aids e Hepatites Virais. Poratdoes do HIV receberão medicamentos logo que o resultado for confirmado. http://www.aids.gov.br/noticia/2014/portadores-do-hiv-receberao- medicamentos-logo-que-o-result ado-confirmado. [Accessed 23 January 2014]
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013, www.who.int/hiv/pub/guidelines/arv2013. [Accessed 26 January 2014]
6. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-postiive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2):1-85.
7. European AIDS Clinical Society. Guidelines version 7.0, October 2013. http://www.eacsociety.org. [Accessed 26 January 2014]
8. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc 2013; 16:18757.
9. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Geneva: World Health Organization; 2002.
10. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. [2006 revision]. Geneva: World Health Organization; 2006, http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. [Accessed 26 January 2014]
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [2010 revision]. Geneva: World Health Organization; 2010, http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf. [Accessed 26 January 2014]
12. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
13. Severe P, Juste MA, Ambroise A, Ellacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 63:257-265.
14. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-1168.
15. Moh R, Danel C, Messou E, Quassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIVinfected adults in West Africa. AIDS 2007; 21:2483-2491.
16. Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SS. Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. AIDS Patient Care STDs 2007; 21:106-115.
17. When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipur MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
19. Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried M. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2013; 4:CD009153.
20. World Health Organization. Guidance on couples HIV testing and counselling: including antiretroviral therapy for treatment and prevention in discordant couples. Recommendations for a public health approach. Geneva: World Health Organization; 2012. [Accessed 26 January 2014]
21. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Chichester, UK: Wiley-Blackwell; 2008.
22. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.htm. [Accessed 8 October 2013]
23. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS 2013; 27:1839-1846.
24. Jain V, Hernán MA, Robins JM, Gelnick LB, Arribas JR, Mora M, et al. Early versus deferred antiretroviral therapy for HIV [Letters]. N Engl J Med 2009; 361:822-824.
25. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64:383-394.
26. Ahdieh-Grant L, Yamashita T, Phair J, Detels R, Wolinsky SM, Margolick JB, et al. When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol 2003; 157:738-746.
27. Althoff K, Justice A, Gange S, Deeks SG, Saag MS, Silverberg MJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24:2469-2479.
28. CASCADE Collaboration. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1500 seroconverters. J Acquir Immune Defic Syndr 2003; 32:303-310.
29. CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171:1560-1569.
30. Cozzi Lepri A, Phillips A, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from ICONA study. AIDS 2001; 15:983-990.
31. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
32. Gallant JE, Hulbert E, Harley C. Health outcomes associated with the timing of antiretroviral therapy initiation [Abstract CDB320]. 6th IAS Conference on HIV Pathogenesis and Treatment, Rome, Italy, 17-20 July 2011.
33. Garća F, de Lazzari E, Plana M, Castro P, Mestre G, Nondedeu M, et al. Long-term CD4R T-cell response to highly active antiretroviral therapy according to baseline CD4R T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-713.
34. Gras L, Kesselring A, Griffin J, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
35. HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-137.
36. HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries. Ann Intern Med 2011; 154:509-515.
37. Kitahata M, Gange S, Abraham A, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
38. Krishnan S, Schouten J, Jacobson D, Benson CA, Collier AC, Koletar SL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-na?̈ve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80:42-49.
39. Merito M, Pezzotti P. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Eur J Health Econ 2006; 7:30-36.
40. Opravil M, Ledergerber B, Furrer H, Hirshel B, Imhof A, Gallant S, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count 350T106/l. AIDS 2002; 16:1371-1381.
41. Palella FJ Jr, Deloria-Knoll M, Chmiel J, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4R cell strata. Ann Intern Med 2003; 138:620-626.
42. Phillips A, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001; 286:2560-2567.
43. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, et al. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39:3-12.
44. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
45. The Antiretroviral Therapy (ART) Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 2009; 52:357-363.
46. Grant P, Tierney C, Katzenstein D, et al. Association of baseline viral load, CD4 count, and Week 4 virologic response (VR) with virologic failure (VF) in ACTG study A5202 [Abstract 535]. 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 27 February-2 March 2011.
47. Hassan AS, Fielding KL, Thuo NM, Nabwera HM, Sanders EJ, Berkley JA. Early loss to follow-up of recently diagnosed HIVinfected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study. Trop Med Int Health 2012; 17: 82-93.
48. Schünemann HJ, Fretheim A, Oxman AD, WHO Advisory Committee on Health Research. Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst 2006; 4:13.
49. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008; 336:924-926.
50. Sinclair D, Isba R, Kredo T, Zani B, Smith H, Garner P. World Health Organization guideline development: an evaluation. PLoS One 2013; 8:e63715.
51. World Health Organization. WHO Handbook for Guideline Development. Geneva: World Health Organization; 2012.
52. Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (1 Suppl):S5-S36.
53. Institut National de la Santé et de la Recherche Médicale-Agence Nationale de Recherches sur le Sida et les Hépatites Virales. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). http://clinicaltrials.gov/show/NCT00495651. [Accessed 3 November 2013]